Examining characteristics and outcomes of patients treated with therapeutic intensification
Characteristics and Results of Patients Treated by Therapeutic Intensification Followed by Autograft of Peripheral Stem Cells and Admitted to Intensive Care and Intensive Care: Single-center Retrospective Analysis
This study looks at patients who received extra treatment before a stem cell transplant for blood cancers to see how they did and what factors might affect their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06894381 on ClinicalTrials.gov |
What this trial studies
This observational study aims to analyze the characteristics and outcomes of patients who have undergone therapeutic intensification followed by autologous stem cell transplantation for malignant hemopathy. It focuses on patients admitted to the Intensive Care Unit within thirty days after receiving chemotherapy. The study will retrospectively gather data from patients treated at the University Hospitals of Strasbourg between 2013 and 2022 to identify potential prognostic factors. The goal is to enhance understanding of patient outcomes in this specific treatment context.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older who have been admitted to the Intensive Care Unit following therapeutic intensification and autograft for hematologic malignancies.
Not a fit: Patients who have opted out of data reuse for scientific research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the prognostic factors affecting outcomes for patients undergoing autologous stem cell transplantation.
How similar studies have performed: While many studies have focused on allogeneic stem cell transplantation, this specific approach to studying autografted patients is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Gender indifferent * Admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy between 01/01/2013 and 12/31/2022 Exclusion Criteria: - Subject having expressed his opposition to the reuse of his data for scientific research purposes
Where this trial is running
Strasbourg
- Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Vincent CASTELAIN, MD, PhD
- Email: vincent.castelain@chru-strasbourg.fr
- Phone: 33.3.88.12.79.15
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.